Update on cardiovascular implantable electronic device infections and their prevention, diagnosis, and management: a scientific statement from the American Heart …

LM Baddour, Z Esquer Garrigos, M Rizwan Sohail… - Circulation, 2024 - Am Heart Assoc
The American Heart Association sponsored the first iteration of a scientific statement that
addressed all aspects of cardiovascular implantable electronic device infection in 2010 …

Cardiac implantable electronic devices

SM Al-Khatib - New England Journal of Medicine, 2024 - Mass Medical Soc
Cardiac Implantable Electronic Devices | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

A modular communicative leadless pacing–defibrillator system

RE Knops, MS Lloyd, PR Roberts… - … England Journal of …, 2024 - Mass Medical Soc
Background The subcutaneous implantable cardioverter–defibrillator (ICD) is associated
with fewer lead-related complications than a transvenous ICD; however, the subcutaneous …

Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective

BJ Maron, NAM Estes, EJ Rowin, MS Maron… - Journal of the American …, 2023 - jacc.org
Implantable cardioverter-defibrillators (ICDs) represent transformational technology,
arguably the most significant advance in cardiovascular medicine in 50 years. The vision …

Postapproval study of a subcutaneous implantable cardioverter-defibrillator system

MR Gold, MF El-Chami, MC Burke… - Journal of the American …, 2023 - jacc.org
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed
to avoid complications related to transvenous implantable cardioverter-defibrillator (TV-ICD) …

[HTML][HTML] Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable …

MS Lloyd, AJ Brisben, VY Reddy… - Heart rhythm O2, 2023 - Elsevier
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) has
demonstrated safety and efficacy for the treatment of malignant ventricular arrhythmias …

Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry

F Migliore, M Biffi, S Viani, R Pittorru, P Francia… - Europace, 2023 - academic.oup.com
Aims Patients with cardiomyopathies and channelopathies are usually younger and have a
predominantly arrhythmia-related prognosis; they have nearly normal life expectancy thanks …

Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects

SL Carroll, B Mondésert, AD Krahn… - European Journal of …, 2024 - academic.oup.com
Abstract Aims Patient-reported outcomes (PROs) provide important insights into patients'
acceptance of their medical devices. Avoid Transvenous Leads in Appropriate Subjects …

Procedure, management, and outcome of subcutaneous implantable cardioverter–defibrillator extraction in clinical practice

P De Filippo, F Migliore, P Palmisano, G Nigro… - Europace, 2023 - academic.oup.com
Aims Subcutaneous implantable cardioverter–defibrillator (S-ICD) therapy is expanding
rapidly. However, there are few data on the S-ICD extraction procedure and subsequent …

[HTML][HTML] Acute human defibrillation performance of a subcutaneous implantable cardioverter-defibrillator with an additional coil electrode

SC Yap, EFJ Oosterwerff, LVA Boersma… - Heart Rhythm, 2023 - Elsevier
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) delivers 80 J
shocks from an 8 cm left-parasternal coil to a 59 cm 3 left lateral pulse generator (PG). A …